Clinical Trials Sponsored by Enversion A/S

Total 2503 results

Novo Nordisk A/S

Completed

A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide

Obesity | Overweight | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors (explorer™5)

Haemophilia A | Haemostasis

United Kingdom, France, United States, Sweden, Spain, Turkey, Japan, Italy, Germany, Thailand, Ukraine
Novo Nordisk A/S

Completed

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Non-alcoholic Steatohepatitis | Hepatobiliary Disorders

United States, Russian Federation, United Kingdom, Denmark, Sweden, Netherlands, Austria, Belgium, Spain, France, Bulgaria, Canada, Australia, Greece, Japan, Finland, Puerto Rico
Novo Nordisk A/S

Completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)

Diabetes Mellitus, Type 2

Sweden, Denmark
Novo Nordisk A/S

Completed

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program (STEP 3)

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Korea, Republic of
Novo Nordisk A/S

Completed

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity (STEP 2)

Obesity | Overweight

United States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
Ambu A/S
QserveCRO

Completed

Single-use Cystoscope System for Direct Visualization of the Urethra and Bladder

Lower Urinary Tract Symptoms | Bladder Cancer | Cystoscope

Denmark
Novo Nordisk A/S

Completed

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea

Diabetes Mellitus, Type 2

Korea, Republic of
Novo Nordisk A/S

Completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice (SURE SPAIN)

Diabetes Mellitus, Type 2

Spain
Novo Nordisk A/S

Completed

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia

Diabetes Mellitus, Type 2

Russian Federation
Novo Nordisk A/S

Completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)

Diabetes Mellitus, Type 2

Switzerland
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

Overweight or Obesity | Metabolism and Nutrition Disorders

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (SUSTAIN 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, Austria, Japan, Norway, Puerto Rico
H. Lundbeck A/S

Completed

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Depressive Disorder, Major

Spain, Hungary, Russian Federation, Bulgaria, Estonia, France, Germany, Italy, Latvia, Poland, Serbia, South Africa, United Kingdom
AJ Vaccines A/S

Completed

Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®)

Poliomyelitis

Panama
Novo Nordisk A/S

Completed

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia (UPDATES)

Diabetes Mellitus, Type 2

Saudi Arabia
ALK-Abelló A/S

Completed

Impact of AIT on Allergic Rhinitis and Asthma

Allergy | Respiratory Disease

Denmark
H. Lundbeck A/S

Completed

Real-life Effectiveness of Vortioxetine in Depression (RELIEVE)

Major Depressive Disorder

United States, Canada, France, Italy
H. Lundbeck A/S

Completed

Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men

Healthy

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes (PIONEER 10)

Diabetes Mellitus, Type 2 | Diabetes

Japan
H. Lundbeck A/S

Completed

A Study in Healthy Men to Investigate Uptake and Distribution of Lu AF88434 in the Brain

Healthy

United Kingdom
Novo Nordisk A/S

Terminated

Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

United States, Germany, United Kingdom
Novo Nordisk A/S

Completed

Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern

Severe Postpartum Haemorrhage

Switzerland
Novo Nordisk A/S

Completed

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, United Kingdom, Canada, Spain, Denmark, Austria, Serbia, South Africa, Sweden, Italy, Bulgaria, Germany, Malaysia
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency

Growth Hormone Disorder | Growth Hormone Deficiency in Children

France, Israel, Austria, Spain, Switzerland, North Macedonia, Norway, Slovenia, Belgium, Sweden
Novo Nordisk A/S

Completed

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Healthy | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Germany
H. Lundbeck A/S

Terminated

Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)

Healthy | Parkinson Disease

Sweden
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (guardian™4)

Congenital Bleeding Disorder | Haemophilia A

United States, Denmark, Austria, Spain, Japan, Brazil, Algeria, Lithuania, Portugal, Russian Federation, Serbia, Turkey, Greece, Hong Kong, Puerto Rico, Hungary, China, Poland
Novo Nordisk A/S

Completed

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (pathfinder™5)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Switzerland, Malaysia, Brazil, Canada, Japan, United Kingdom, Israel, Portugal, Ukraine, Greece, Lithuania, Puerto Rico, Turkey, Italy
Novo Nordisk A/S

Completed

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. (REAL 1)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

United States, Poland, India, Japan, Russian Federation, United Kingdom, Germany, Sweden, Israel, Malaysia, Turkey, South Africa, Australia, Latvia, Lithuania, Romania, Brazil, Norway, Ukraine
RSP Systems A/S

Completed

Performance Study of a Non-invasive Glucose Monitoring Device Prototype

Diabetes Mellitus

Denmark
H. Lundbeck A/S

Terminated

Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms

Schizophrenia

Bulgaria, Estonia, Hungary, Latvia, Ukraine, Germany, Poland
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus (DUALTM IX)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Spain, Switzerland, Argentina, Finland, Hungary, Russian Federation, Slovenia, Slovakia
Novo Nordisk A/S

Completed

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

Noonan Syndrome | Genetic Disorder

Japan
Novo Nordisk A/S

Completed

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. (pathfinder™3)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, United Kingdom, Croatia, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Italy, Japan, Norway, Bulgaria
Novo Nordisk A/S

Withdrawn

A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria (B Simple)

Diabetes Mellitus, Type 2

Algeria
H. Lundbeck A/S

Completed

Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy Subjects

Healthy

France
H. Lundbeck A/S

Completed

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Study With Vortioxetine on Emotional Functioning in Patients With Depression (COMPLETE)

Major Depressive Disorder

France, Italy, Lithuania, Spain
Novo Nordisk A/S

Completed

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) (DUAL™ II China)

Diabetes Mellitus, Type 2 | Diabetes

Hong Kong, China
Novo Nordisk A/S

Completed

A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects

Healthy

China
Novo Nordisk A/S

Completed

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A (alleviate 1)

Congenital Bleeding Disorder | Haemophilia A

United States, Austria, Serbia, Germany, Japan, France
H. Lundbeck A/S

Completed

A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects

Parkinson Disease

Sweden
Novo Nordisk A/S

Completed

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

Obesity | Overweight | Healthy Volunteers

United States
Novo Nordisk A/S

Completed

RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan (RESILIENT)

Diabetes Mellitus, Type 2

Japan

3

Subscribe